Orchard Therapeutics IPO

10/30/2018

IPO

$200,000,000

To fund the ongoing development of our product candidates, including completing registrational trials and submitting for regulatory approvals in the United States and Europe for OTL-101 for ADA-SCID, OTL-200 for MLD and OTL-103 for WAS, establishing clinical proof of concept for OTL-102, further progressing OTL-300, OTL-201 and OTL-202 and advancing our preclinical programs; to fund the ongoing commercialization of Strimvelis in the European Union and to expand our marketing and sales infrastructure in key markets, including the United States and Europe, in preparation for the potential commercial approval of OTL-101, OTL-200 and OTL-103; to fund the design, construction, and operation of our own manufacturing facility, including the necessary laboratory and manufacturing equipment, to support our long-term capacity needs for our product pipeline; and to fund ongoing business development activities, general and administrative expenses, working capital and other general corporate purpos

Publicly-held

Biopharmaceutical

101 Seaport Blvd. 7th Floor
Boston, MA 02210
USA

Undisclosed

Orchard Therapeutics (Nasdaq: ORTX) is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.